Update on AUA guideline on the management of benign prostatic hyperplasia

Kevin T. McVary, Claus Roehrborn, Andrew L. Avins, Michael J. Barry, Reginald C. Bruskewitz, Robert F. Donnell, Harris E. Foster, Chris M. Gonzalez, Steven A. Kaplan, David F. Penson, James C. Ulchaker, John T. Wei

Research output: Contribution to journalArticle

646 Citations (Scopus)

Abstract

Purpose: To revise the 2003 version of the American Urological Association's (AUA) Guideline on the management of benign prostatic hyperplasia (BPH). Materials and Methods: From MEDLINE® searches of English language publications (January 1999 through February 2008) using relevant MeSH terms, articles concerning the management of the index patient, a male <45 years of age who is consulting a healthcare provider for lower urinary tract symptoms (LUTS) were identified. Qualitative analysis of the evidence was performed. Selected studies were stratified by design, comparator, follow-up interval, and intensity of intervention, and meta-analyses (quantitative synthesis) of outcomes of randomized controlled trials were planned. Guideline statements were drafted by an appointed expert Panel based on the evidence. Results: The studies varied as to patient selection; randomization; blinding mechanism; run-in periods; patient demographics, comorbidities, prostate characteristics and symptoms; drug doses; other intervention characteristics; comparators; rigor and intervals of follow-up; trial duration and timing; suspected lack of applicability to current US practice; and techniques of outcomes measurement. These variations affected the quality of the evidence reviewed making formal meta-analysis impractical or futile. Instead, the Panel and extractors reviewed the data in a systematic fashion and without statistical rigor. Diagnosis and treatment algorithms were adopted from the 2005 International Consultation of Urologic Diseases. Guideline statements concerning pharmacotherapies, watchful waiting, surgical options and minimally invasive procedures were either updated or newly drafted, peer reviewed and approved by AUA Board of Directors. Conclusions: New pharmacotherapies and technologies have emerged which have impacted treatment algorithms. The management of LUTS/BPH continues to evolve.

Original languageEnglish (US)
Pages (from-to)1793-1803
Number of pages11
JournalJournal of Urology
Volume185
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

Prostatic Hyperplasia
Lower Urinary Tract Symptoms
Guidelines
Meta-Analysis
Watchful Waiting
Urologic Diseases
Drug Therapy
Minimally Invasive Surgical Procedures
Random Allocation
MEDLINE
Health Personnel
Patient Selection
Publications
Comorbidity
Prostate
Language
Referral and Consultation
Randomized Controlled Trials
Demography
Technology

Keywords

  • 5-alpha-reductase inhibitors
  • adrenergic alpha-antagonists
  • behavior therapy
  • prostatic hyperplasia
  • transurethral resection of prostate
  • urinary retention

ASJC Scopus subject areas

  • Urology

Cite this

McVary, K. T., Roehrborn, C., Avins, A. L., Barry, M. J., Bruskewitz, R. C., Donnell, R. F., ... Wei, J. T. (2011). Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology, 185(5), 1793-1803. https://doi.org/10.1016/j.juro.2011.01.074

Update on AUA guideline on the management of benign prostatic hyperplasia. / McVary, Kevin T.; Roehrborn, Claus; Avins, Andrew L.; Barry, Michael J.; Bruskewitz, Reginald C.; Donnell, Robert F.; Foster, Harris E.; Gonzalez, Chris M.; Kaplan, Steven A.; Penson, David F.; Ulchaker, James C.; Wei, John T.

In: Journal of Urology, Vol. 185, No. 5, 05.2011, p. 1793-1803.

Research output: Contribution to journalArticle

McVary, KT, Roehrborn, C, Avins, AL, Barry, MJ, Bruskewitz, RC, Donnell, RF, Foster, HE, Gonzalez, CM, Kaplan, SA, Penson, DF, Ulchaker, JC & Wei, JT 2011, 'Update on AUA guideline on the management of benign prostatic hyperplasia', Journal of Urology, vol. 185, no. 5, pp. 1793-1803. https://doi.org/10.1016/j.juro.2011.01.074
McVary, Kevin T. ; Roehrborn, Claus ; Avins, Andrew L. ; Barry, Michael J. ; Bruskewitz, Reginald C. ; Donnell, Robert F. ; Foster, Harris E. ; Gonzalez, Chris M. ; Kaplan, Steven A. ; Penson, David F. ; Ulchaker, James C. ; Wei, John T. / Update on AUA guideline on the management of benign prostatic hyperplasia. In: Journal of Urology. 2011 ; Vol. 185, No. 5. pp. 1793-1803.
@article{9cd46ca1bbf145a3950830d44a7938b6,
title = "Update on AUA guideline on the management of benign prostatic hyperplasia",
abstract = "Purpose: To revise the 2003 version of the American Urological Association's (AUA) Guideline on the management of benign prostatic hyperplasia (BPH). Materials and Methods: From MEDLINE{\circledR} searches of English language publications (January 1999 through February 2008) using relevant MeSH terms, articles concerning the management of the index patient, a male <45 years of age who is consulting a healthcare provider for lower urinary tract symptoms (LUTS) were identified. Qualitative analysis of the evidence was performed. Selected studies were stratified by design, comparator, follow-up interval, and intensity of intervention, and meta-analyses (quantitative synthesis) of outcomes of randomized controlled trials were planned. Guideline statements were drafted by an appointed expert Panel based on the evidence. Results: The studies varied as to patient selection; randomization; blinding mechanism; run-in periods; patient demographics, comorbidities, prostate characteristics and symptoms; drug doses; other intervention characteristics; comparators; rigor and intervals of follow-up; trial duration and timing; suspected lack of applicability to current US practice; and techniques of outcomes measurement. These variations affected the quality of the evidence reviewed making formal meta-analysis impractical or futile. Instead, the Panel and extractors reviewed the data in a systematic fashion and without statistical rigor. Diagnosis and treatment algorithms were adopted from the 2005 International Consultation of Urologic Diseases. Guideline statements concerning pharmacotherapies, watchful waiting, surgical options and minimally invasive procedures were either updated or newly drafted, peer reviewed and approved by AUA Board of Directors. Conclusions: New pharmacotherapies and technologies have emerged which have impacted treatment algorithms. The management of LUTS/BPH continues to evolve.",
keywords = "5-alpha-reductase inhibitors, adrenergic alpha-antagonists, behavior therapy, prostatic hyperplasia, transurethral resection of prostate, urinary retention",
author = "McVary, {Kevin T.} and Claus Roehrborn and Avins, {Andrew L.} and Barry, {Michael J.} and Bruskewitz, {Reginald C.} and Donnell, {Robert F.} and Foster, {Harris E.} and Gonzalez, {Chris M.} and Kaplan, {Steven A.} and Penson, {David F.} and Ulchaker, {James C.} and Wei, {John T.}",
year = "2011",
month = "5",
doi = "10.1016/j.juro.2011.01.074",
language = "English (US)",
volume = "185",
pages = "1793--1803",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Update on AUA guideline on the management of benign prostatic hyperplasia

AU - McVary, Kevin T.

AU - Roehrborn, Claus

AU - Avins, Andrew L.

AU - Barry, Michael J.

AU - Bruskewitz, Reginald C.

AU - Donnell, Robert F.

AU - Foster, Harris E.

AU - Gonzalez, Chris M.

AU - Kaplan, Steven A.

AU - Penson, David F.

AU - Ulchaker, James C.

AU - Wei, John T.

PY - 2011/5

Y1 - 2011/5

N2 - Purpose: To revise the 2003 version of the American Urological Association's (AUA) Guideline on the management of benign prostatic hyperplasia (BPH). Materials and Methods: From MEDLINE® searches of English language publications (January 1999 through February 2008) using relevant MeSH terms, articles concerning the management of the index patient, a male <45 years of age who is consulting a healthcare provider for lower urinary tract symptoms (LUTS) were identified. Qualitative analysis of the evidence was performed. Selected studies were stratified by design, comparator, follow-up interval, and intensity of intervention, and meta-analyses (quantitative synthesis) of outcomes of randomized controlled trials were planned. Guideline statements were drafted by an appointed expert Panel based on the evidence. Results: The studies varied as to patient selection; randomization; blinding mechanism; run-in periods; patient demographics, comorbidities, prostate characteristics and symptoms; drug doses; other intervention characteristics; comparators; rigor and intervals of follow-up; trial duration and timing; suspected lack of applicability to current US practice; and techniques of outcomes measurement. These variations affected the quality of the evidence reviewed making formal meta-analysis impractical or futile. Instead, the Panel and extractors reviewed the data in a systematic fashion and without statistical rigor. Diagnosis and treatment algorithms were adopted from the 2005 International Consultation of Urologic Diseases. Guideline statements concerning pharmacotherapies, watchful waiting, surgical options and minimally invasive procedures were either updated or newly drafted, peer reviewed and approved by AUA Board of Directors. Conclusions: New pharmacotherapies and technologies have emerged which have impacted treatment algorithms. The management of LUTS/BPH continues to evolve.

AB - Purpose: To revise the 2003 version of the American Urological Association's (AUA) Guideline on the management of benign prostatic hyperplasia (BPH). Materials and Methods: From MEDLINE® searches of English language publications (January 1999 through February 2008) using relevant MeSH terms, articles concerning the management of the index patient, a male <45 years of age who is consulting a healthcare provider for lower urinary tract symptoms (LUTS) were identified. Qualitative analysis of the evidence was performed. Selected studies were stratified by design, comparator, follow-up interval, and intensity of intervention, and meta-analyses (quantitative synthesis) of outcomes of randomized controlled trials were planned. Guideline statements were drafted by an appointed expert Panel based on the evidence. Results: The studies varied as to patient selection; randomization; blinding mechanism; run-in periods; patient demographics, comorbidities, prostate characteristics and symptoms; drug doses; other intervention characteristics; comparators; rigor and intervals of follow-up; trial duration and timing; suspected lack of applicability to current US practice; and techniques of outcomes measurement. These variations affected the quality of the evidence reviewed making formal meta-analysis impractical or futile. Instead, the Panel and extractors reviewed the data in a systematic fashion and without statistical rigor. Diagnosis and treatment algorithms were adopted from the 2005 International Consultation of Urologic Diseases. Guideline statements concerning pharmacotherapies, watchful waiting, surgical options and minimally invasive procedures were either updated or newly drafted, peer reviewed and approved by AUA Board of Directors. Conclusions: New pharmacotherapies and technologies have emerged which have impacted treatment algorithms. The management of LUTS/BPH continues to evolve.

KW - 5-alpha-reductase inhibitors

KW - adrenergic alpha-antagonists

KW - behavior therapy

KW - prostatic hyperplasia

KW - transurethral resection of prostate

KW - urinary retention

UR - http://www.scopus.com/inward/record.url?scp=79953768905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953768905&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2011.01.074

DO - 10.1016/j.juro.2011.01.074

M3 - Article

C2 - 21420124

AN - SCOPUS:79953768905

VL - 185

SP - 1793

EP - 1803

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -